Abstract
Inherited thrombophilias are not yet established as a cause of placenta-mediated pregnancy complications, such as fetal growth restriction, preeclampsia, abruption, and pregnancy loss. An inherited thrombophilia is only one of many factors that lead to development of these diseases and is unlikely to be the unique factor that should drive management in subsequent pregnancies. The paucity of evidence for benefit, coupled with a small potential for harm, suggests that low molecular weight heparin should be considered an experimental drug for these indications until data from controlled trials are published. At present, women with a history of placenta-mediated pregnancy complications, with or without a thrombophilia, should be followed closely without routine prophylactic low molecular weight heparin other than for prevention of venous thromboembolism in limited circumstances.
| Original language | English |
|---|---|
| Pages (from-to) | 320-324 |
| Number of pages | 5 |
| Journal | Obstetrics and Gynecology |
| Volume | 112 |
| Issue number | 2 PART 1 |
| DOIs | |
| Publication status | Published - Aug 2008 |
Fingerprint
ASJC Scopus subject areas
- Obstetrics and Gynaecology
Cite this
Inherited thrombophilia and pregnancy complications revisited. / Rodger, Marc A.; Paidas, Michael; Claire, McLintock; Middeldorp, Saskia; Kahn, Susan; Martinelli, Ida; Hague, William; Rosene Montella, Karen; Greer, Ian.
In: Obstetrics and Gynecology, Vol. 112, No. 2 PART 1, 08.2008, p. 320-324.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Inherited thrombophilia and pregnancy complications revisited
AU - Rodger, Marc A.
AU - Paidas, Michael
AU - Claire, McLintock
AU - Middeldorp, Saskia
AU - Kahn, Susan
AU - Martinelli, Ida
AU - Hague, William
AU - Rosene Montella, Karen
AU - Greer, Ian
PY - 2008/8
Y1 - 2008/8
N2 - Inherited thrombophilias are not yet established as a cause of placenta-mediated pregnancy complications, such as fetal growth restriction, preeclampsia, abruption, and pregnancy loss. An inherited thrombophilia is only one of many factors that lead to development of these diseases and is unlikely to be the unique factor that should drive management in subsequent pregnancies. The paucity of evidence for benefit, coupled with a small potential for harm, suggests that low molecular weight heparin should be considered an experimental drug for these indications until data from controlled trials are published. At present, women with a history of placenta-mediated pregnancy complications, with or without a thrombophilia, should be followed closely without routine prophylactic low molecular weight heparin other than for prevention of venous thromboembolism in limited circumstances.
AB - Inherited thrombophilias are not yet established as a cause of placenta-mediated pregnancy complications, such as fetal growth restriction, preeclampsia, abruption, and pregnancy loss. An inherited thrombophilia is only one of many factors that lead to development of these diseases and is unlikely to be the unique factor that should drive management in subsequent pregnancies. The paucity of evidence for benefit, coupled with a small potential for harm, suggests that low molecular weight heparin should be considered an experimental drug for these indications until data from controlled trials are published. At present, women with a history of placenta-mediated pregnancy complications, with or without a thrombophilia, should be followed closely without routine prophylactic low molecular weight heparin other than for prevention of venous thromboembolism in limited circumstances.
UR - http://www.scopus.com/inward/record.url?scp=51649086196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=51649086196&partnerID=8YFLogxK
U2 - 10.1097/AOG.0b013e31817e8acc
DO - 10.1097/AOG.0b013e31817e8acc
M3 - Article
C2 - 18669729
AN - SCOPUS:51649086196
VL - 112
SP - 320
EP - 324
JO - Obstetrics and Gynecology
JF - Obstetrics and Gynecology
SN - 0029-7844
IS - 2 PART 1
ER -